A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...

The company’s FLASH2 study was stopped early after failing to show efficacy, shifting focus toward strategic alternatives and ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte ...

Meta-analysis of randomized controlled trials (RCTs) to evaluate the incidence of hemorrhage and venous thromboembolism (VTE) events in patients with gastrointestinal (GI) cancers treated with ...

SELLAS Life Science announced that the pre-specified threshold of 60 events has been reached in its ongoing Phase 3 REGAL clinical trial of galinpepimut-S, GPS, in acute myeloid leukemia, AML, ...

IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...

Presentation reinforces ATH434's clinical profile ahead of Phase 3 engagement with regulators - MELBOURNE, Australia and SAN FRANCISCO, April 22, 2026 (GLOBE NEWSWIRE)-- Alterity Therapeutics (ASX: ...